Is Polyethylene glycol the active ingredient in Miralax (Polyethylene glycol 3350)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yes, Polyethylene Glycol 3350 is the Active Ingredient in MiraLAX

Polyethylene glycol 3350 (PEG 3350) is indeed the active ingredient in MiraLAX, as confirmed by FDA labeling. 1

Product Identity and Formulation

  • MiraLAX contains 17 grams of polyethylene glycol 3350 per dose, whether dispensed in bottle form (measured with a cap filled to the line) or in individual packets 1
  • The FDA-approved labeling explicitly identifies "Polyethylene Glycol 3350" as the active ingredient in this over-the-counter osmotic laxative 1

Mechanism of Action

  • PEG 3350 is a long-chain polymer of ethylene oxide that functions as an osmotic laxative by sequestering fluid in the bowel 2
  • It increases the amount of water in the large bowel, either by drawing fluid from the body into the bowel or by retaining administered fluid 2
  • The compound is an inert polymer that does not undergo significant systemic absorption 2

Clinical Evidence and Efficacy

  • PEG 3350 at 17 grams daily is safe and effective for both short-term and chronic constipation treatment, with demonstrated efficacy extending up to 12 months without evidence of tachyphylaxis 3, 4
  • In chronic constipation trials, 52% of PEG-treated patients achieved treatment success compared to 11% with placebo (p<0.001) over 6 months 3
  • The response is durable over time, with 80-88% of patients reporting successful treatment across multiple months of observation 4

Safety Profile

  • Laboratory monitoring shows no clinically significant changes in electrolytes, hematology, or blood chemistry even with chronic use up to 12 months 3, 4
  • The most common adverse effects are mild-to-moderate gastrointestinal complaints including diarrhea, flatulence, and nausea, which are not significantly different from placebo in most studies 3, 5
  • No cases of incontinence or severe cramping were reported even at higher doses (up to 85 grams) 6

Important Clinical Considerations

  • The standard dose of 17 grams must be mixed with 8 ounces of liquid for proper administration 7
  • Many treatment failures occur because patients do not mix PEG with sufficient liquid—this is a critical pitfall to avoid 7
  • PEG 3350 is available over-the-counter in the United States and is widely used for occasional constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation 2

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.